Ketamine: Mechanisms and Relevance to Treatment of Depression.
Kim JW, Suzuki K, Kavalali ET, Monteggia LM.
Annu Rev Med. 2024 Jan 29;75:129-143. doi: 10.1146/annurev-med-051322-120608. Epub 2023 Sep 20.
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr, Stahl S.
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Bahji A, Vazquez GH, Zarate CA Jr.
J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23.
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.
Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA.
Lancet Psychiatry. 2022 Nov;9(11):907-921. doi: 10.1016/S2215-0366(22)00317-0.
Overdoses and deaths related to the use of ketamine and its analogues: a systematic review.
Chaves TV, Wilffert B, Sanchez ZM.
Am J Drug Alcohol Abuse. 2023 Mar 4;49(2):141-150. doi: 10.1080/00952990.2022.2132506. Epub 2022 Nov 21.
Therapeutic Mechanisms of Ketamine.
Mihaljević S, Pavlović M, Reiner K, Ćaćić M.
Psychiatr Danub. 2020 Autumn-Winter;32(3-4):325-333. doi: 10.24869/psyd.2020.325.
Ketamine in neuropsychiatric disorders: an update.
Johnston JN, Kadriu B, Kraus C, Henter ID, Zarate CA Jr.
Neuropsychopharmacology. 2024 Jan;49(1):23-40. doi: 10.1038/s41386-023-01632-1. Epub 2023 Jun 20.
Esketamine for treatment resistant depression.
Swainson J, Thomas RK, Archer S, Chrenek C, MacKay MA, Baker G, Dursun S, Klassen LJ, Chokka P, Demas ML.
Expert Rev Neurother. 2019 Oct;19(10):899-911. doi: 10.1080/14737175.2019.1640604. Epub 2019 Jul 16.
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G.
J Neurosci. 2021 Feb 3;41(5):891-900. doi: 10.1523/JNEUROSCI.1659-20.2020. Epub 2020 Nov 30.
Ketamine: A tale of two enantiomers.
Jelen LA, Young AH, Stone JM.
J Psychopharmacol. 2021 Feb;35(2):109-123. doi: 10.1177/0269881120959644. Epub 2020 Nov 6.
